IGF1R
IGF1R (insulin-Like growth factor 1 receptor) is a receptor tyrosine kinase that bind to insulin-like growth factor 1 with high affinity. It plays a vital role in in cell growth, cell survival and malignant transformation etc.
Products for IGF1R
- Cat.No. Product Name Information
- GC13697 AG-1024 Selective IGF-1R inhibitor
- GC17045 AXL1717 A potent and selective inhibitor of IGF-1R
- GC33072 AZ7550 AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
- GC34287 AZ7550 hydrochloride AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
- GC34414 AZ7550 Mesylate (AZ7550 trimesylate salt)
- GC14189 AZD-3463 ALK/IGF1R inhibitor
-
GC17773
BMS-536924
IR/IGF-1R inhibitor
- GC16712 BMS-754807 IGF-1R/InsR inhibitor,potent and selective
- GC45789 Ceritinib-d7 An internal standard for the quantification of ceritinib
- GC31706 Ginsenoside Rg5 A ginsenoside with diverse biological activities
- GC12273 GSK1838705A IGF-IR/IR/ALK inhibitor, ATP-competitive
- GC17612 GSK1904529A Selective IGF-1R/IR inhibitor
- GC63297 I-OMe-Tyrphostin AG 538 I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase).
- GC36311 Indirubin Derivative E804 Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor (IGF1R), with an IC50 of 0.65 μM for IGF1R.
- GC14552 LDK378 LDK378 (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM.
- GC17452 LDK378 dihydrochloride
- GC15749 Linsitinib IGF1R/IR inhibitor,potent and novel
- GC61111 NBI-31772 hydrate NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs).
- GC12712 NT157 IRS-1/2 inhibitor, inhibits IGF-1R and STAT3 signaling pathway
- GC14310 NVP-ADW742 Selective IGF-1R inhibitor
- GC12963 NVP-AEW541 IGF-IR inhibitor, novel, potent and selective
- GC16991 PQ 401 IGF1R inhibitor,potent and cell-permeable
-
GC69825
Robatumumab
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor 1 receptor) antibody. Robatumumab has anti-tumor activity and anti-cancer cell proliferation activity. Robatumumab can be used for research on osteosarcoma and Ewing's sarcoma.
- GC25881 S961 S961 is a biosynthetic insulin receptor antagonist that inhibits cellular proliferation and colony formation in breast tumour cells.
- GC16821 TAE226(NVP-TAE226) TAE226(NVP-TAE226) (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC50s of 5.5 nM and 140 nM, respectively.
-
GC70013
Teprotumumab
Teprotumumab is a human monoclonal antibody that blocks the insulin-like growth factor-1 receptor (IGF-1R). Teprotumumab binds to the ligand-binding domain of the extracellular alpha subunit of IGF-1R. It inhibits the actions of TSH and IGF-1 in fibroblasts. Teprotumumab reduces the expression of IL-6 and IL-8, which are dependent on TSH, as well as phosphorylation of Akt. It can be used for research related to thyroid-associated eye disease.
-
GC70151
Xentuzumab
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant humanized monoclonal antibody that targets the IGF ligands IGF1 and IGF2. Xentuzumab inhibits the growth-promoting signals of both IGF1 and IGF2, suppressing the activation of AKT.
- GC13102 XL228 A tyrosine kinase inhibitor